News

Saint Luke's is seeing success with a voucher program in collaboration with Kanbe’s Markets, a nonprofit organization that provides access to fresh, affordable, and healthy foods to help reduce food insecurity.

A potassium binder helped patients with heart failure who have or are at high risk for hyperkalemia stay on spironolactone at an optimal dose, but showed a signal of HF hospitalization risk.

A secondary analysis of the pooled STEP-HFpEF and STEP-HFpEF DM trials showed the greatest improvements in those with the most weight loss at 52 weeks.

BBC News talked to Dr. Mikhail Kosiborod about new findings on the cardiovascular effects of semaglutide.

A new subanalysis presented by Dr. Mikhail Kosiborod shows benefits of semaglutide in patients with atrial fibrillation.

On average, survival benefits of CPR for cardiac arrest could be three times as high for white adults compared to Black adults and twice as high for men compared to women.

Semaglutide improves symptoms in both men and women who present with heart failure. When it comes to weight loss, however, the drug appears to benefit women much more than men.

Consumer Reports On Health talked to Dr. Bethany Austin and Austin Workman about strategies to improve quality of life for those living with heart failure.

Dr. Matthew Wilkinson, a transplant surgeon at Saint Luke’s talks about the advances in organ donation and the importance of living organ donation.

The popular weight loss drug Wegovy seems to provide more health benefits for people who have diabetes and a common kind of heart failure than just helping take off the pounds, according to the results from the STEP HFpEF DM trial.